시장보고서

상품코드

1679358

감염성 질환 분자 진단 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Infectious Disease Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product, By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2025년 02월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

감염성 질환 분자 진단 시장의 성장 및 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 감염성 질환 분자 진단 시장 규모는 2030년까지 201억 5,000만 달러에 달할 것으로 예측되고, 2025-2030년 CAGR 3.37%로 성장할 전망입니다. 이 시장은 기술적으로 발전된 제품의 도입과 PoC 환경에서 분자 진단에 대한 수요 증가에 의해 주도되고 있습니다.

휴대성, 정확한 결과, 비용 효율성을 갖춘 빠른 기술 발전은 감염성 질환 분자 진단 시장의 중요한 동인으로 작용할 것으로 예상됩니다. 기업들은 구체적이고 정확한 결과를 얻기 위해 새로운 기술을 구현하여 제품을 업그레이드하고 있습니다. 주요 업체들은 신종 질병을 겨냥한 새로운 키트 개발을 위한 R&D를 강화하거나 다른 키트 제조 회사와 계약을 체결하여 PCR 기기용 제품 포트폴리오를 업데이트하고 있습니다.

INAAT, 질량 분석법, ISH와 같은 기술은 다른 기존 진단 테스트에 비해 위양성률이 낮고 발전된 기술입니다. 이 기술의 비용 효율성과 사용자 편의성, 정확도 등의 장점으로 인해 이 기술의 채택이 증가할 것으로 예상됩니다.

연구 기관에서 분자 진단의 사용이 증가하고 있습니다. PCR, 웨스턴 블롯팅, 서던 블롯팅과 같은 기술의 사용이 보편화되고 있습니다. 또한, 전 세계적으로 SARS-CoV-2 감염이 확산되면서 혁신적인 분자 진단을 찾기 위한 각국 정부와 진단 회사의 연구 자금이 증가하고 있습니다.

분자 진단은 효과적이고 정확한 결과를 제공합니다. 또한 이러한 검사는 질병을 조기에 발견할 수 있어 대체품의 위협이 적습니다. 그러나 이러한 검사의 높은 가격은 환자들이 외부 대체품으로 전환하도록 유도할 것으로 예상됩니다. 또한 SARS-CoV-2와 같은 신종 감염을 탐지하는 경우 내부 대체율이 높아 경쟁이 치열해집니다.

감염성 질환 분자 진단 시장 보고서 하이라이트

시약은 2024년 25.86%의 매출 점유율로 시장을 주도했으며, 감염성 질환 진단에 널리 사용됨에 따라 예측 기간 동안 가장 빠른 CAGR을 경험할 것으로 예상됩니다.
중합효소 연쇄반응(PCR) 기술은 COVID-19, HIV, 간염 및 결핵을 포함한 광범위한 전염병을 감지하는데 널리 적용되어 2024년에 지배적인 수익 점유율을 확보했습니다.
호흡기 질환은 2024년에 71.96%의 가장 큰 시장 점유율을 차지할 것으로 예상되며, 이는 주로 호흡기 세포융합 바이러스(RSV), 인플루엔자, COVID-19 등과 같은 호흡기 감염성 질환의 유병률 증가에 기인합니다.
2024년에는 진단 연구소가 정확하고 시기 적절한 진단이 필요한 HIV, 간염, 결핵, 호흡기 감염과 같은 전염병의 유병률 증가에 힘입어 가장 높은 매출 점유율을 차지할 것으로 예상됩니다.
북미의 감염성 질환 분자 진단 시장은 코로나19, 인플루엔자, HIV, 간염 등 감염성 질환의 높은 유병률로 인해 2024년 매출 점유율의 40.95%를 차지할 것으로 예상됩니다.

부문 대시보드
감염성 질환 분자 진단 시장 : 기술 변동 분석(2024년, 2030년)
중합효소 연쇄반응(PCR)
- 다중 PCR
- 기타 PCR
현장 하이브리드화
- 기기
- 시약
- 기타
등온 핵산 증폭 기술(INAAT)
- 기기
- 시약
- 기타
칩 및 마이크로 어레이이
- 기기
- 시약
- 기타
질량 분석
- 기기
- 시약
- 기타
시퀀싱
- 기기
- 시약
- 기타
전사 매개 증폭
- 기기
- 시약
- 기타
기타
- 기기
- 시약
- 기타

제6장 감염성 질환 분자 진단 시장 : 용도별, 추정 및 동향 분석

부문 대시보드
감염성 질환 분자 진단 시장 : 용도 변동 분석(2024년, 2030년)
호흡기 질환
결핵
수막염
소화관 감염성 질환
HPV
성감염성 질환
패혈증
약제 내성 질환
기타

제7장 감염성 질환 분자 진단 시장 : 최종 용도별, 추정 및 동향 분석

부문 대시보드
감염성 질환 분자 진단 시장 : 최종 용도 변동 분석(2024년, 2030년)
병원
클리닉
진단 실험실
연구기관

제8장 감염성 질환 분자 진단 시장 : 지역별, 추정 및 동향 분석

감염성 질환 분자 진단 시장 점유율, 지역별(2024년, 2030년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제9장 경쟁 구도

주요 시장 진출기업에 의한 최근의 동향과 영향 분석
기업 분류
기업 히트맵 분석
기업 프로파일
- Abbott
- Danaher Corporation
- bioMerieux SA
- F. Hoffmann-La Roche Ltd
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Becton, Dickinson and Company
- Hologic, Inc.(Gen-Probe)
- Grifols SA
- Qiagen
- Siemens Healthineers AG
- Sysmex Corporation

HBR 25.04.11

Infectious Disease Molecular Diagnostics Market Growth & Trends:

The global infectious disease molecular diagnostics market size is expected to reach USD 20.15 billion by 2030, registering a CAGR of 3.37% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the introduction of technologically advanced products and an increase in demand for molecular diagnostics in PoC settings.

Rapid technological advancements with portability, accurate results, and cost-effectiveness are anticipated to serve as crucial drivers of the market for infectious disease molecular diagnostics. Companies are upgrading their products by implementing new techniques to gain specific and accurate results. Key players are updating their product portfolio for PCR instruments with increased R&D initiatives for developing novel kits to target emerging diseases or by entering into agreements with other kit manufacturing companies.

Technologies such as INAAT, mass spectroscopy, and ISH are advanced and have a low false-positive rate as compared to other traditional diagnostic tests. Advantages such as the cost-effectiveness and user-friendliness of this technology and the accuracy offered are estimated to increase the adoption of this technology.

The use of molecular diagnostics in research institutes is increasing. The use of techniques such as PCR, western blotting, and southern blotting is becoming common. Moreover, the spread of SARS-CoV-2 infection globally has led to an increase in research funding by governments as well as diagnostic companies to search for innovative molecular diagnostics.

Molecular diagnostics deliver effective and accurate results. Moreover, these tests enable the early detection of diseases, maintaining a low threat of substitutes. However, the high prices of these tests are expected to encourage patients to shift to external substitutes. Moreover, for the detection of newer infections such as SARS-CoV-2, the rate of internal substitution is high, which boosts competitive rivalry.

Infectious Disease Molecular Diagnostics Market Report Highlights:

Reagents led the market with a 25.86% revenue share in 2024 and are projected to experience the fastest CAGR over the forecast period due to their widespread use in infectious disease diagnostics.
Polymerase Chain Reaction (PCR) technology secured the dominant revenue share in 2024 owing to its widespread application in detecting a broad range of infectious diseases, including COVID-19, HIV, hepatitis, and tuberculosis.
Respiratory diseases held the largest market share of 71.96% in 2024, driven primarily by the rising prevalence of respiratory infectious diseases such as Respiratory Syncytial Virus (RSV), influenza, COVID-19, etc.
Diagnostic laboratories held the dominant revenue share in 2024, driven by the rising prevalence of infectious diseases such as HIV, hepatitis, tuberculosis, and respiratory infections, which require accurate and timely diagnosis.
North America infectious disease molecular diagnosis market accounted for 40.95% of the revenue share in 2024, driven by the high prevalence of infectious diseases such as COVID-19, influenza, HIV, and hepatitis.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Infectious Disease Molecular Diagnostics Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Infectious Disease Molecular Diagnostics Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Infectious Disease Molecular Diagnostics Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Infectious Disease Molecular Diagnostics Market: Product Movement Analysis, 2024 & 2030 (USD Million)
4.3. Instruments
- 4.3.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Reagents
- 4.4.1. Reagents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Services
- 4.5.1. Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Infectious Disease Molecular Diagnostics Market: Technology Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Infectious Disease Molecular Diagnostics Market: Technology Movement Analysis, 2024 & 2030 (USD Million)
5.3. Polymerase Chain Reaction (PCR)
- 5.3.1. Polymerase Chain Reaction (PCR) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.2. Multiplex PCR
  - 5.3.2.1. Multiplex PCR Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 5.3.2.2. Instruments
    - 5.3.2.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 5.3.2.3. Reagents
    - 5.3.2.3.1. Reagents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 5.3.2.4. Others
    - 5.3.2.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.3. Other PCR
5.4. In Situ Hybridization
- 5.4.1. In Situ Hybridization Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.2. Instruments
  - 5.4.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.3. Reagents
  - 5.4.3.1. Reagents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.4. Others
  - 5.4.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Isothermal Nucleic Acid Amplification Technology (INAAT)
- 5.5.1. Isothermal Nucleic Acid Amplification Technology (INAAT) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5.2. Instruments
  - 5.5.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5.3. Reagents
  - 5.5.3.1. Reagents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5.4. Others
  - 5.5.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Chips and Microarrays
- 5.6.1. Chips and Microarrays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6.2. Instruments
  - 5.6.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6.3. Reagents
  - 5.6.3.1. Reagents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6.4. Others
  - 5.6.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Mass Spectrometry
- 5.7.1. Mass Spectrometry Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7.2. Instruments
  - 5.7.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7.3. Reagents
  - 5.7.3.1. Reagents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7.4. Others
  - 5.7.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Sequencing
- 5.8.1. Sequencing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.8.2. Instruments
  - 5.8.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.8.3. Reagents
  - 5.8.3.1. Reagents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.8.4. Others
  - 5.8.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Transcription Mediated Amplification
- 5.9.1. Transcription Mediated Amplification Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.9.2. Instruments
  - 5.9.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.9.3. Reagents
  - 5.9.3.1. Reagents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.9.4. Others
  - 5.9.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.10. Others
- 5.10.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.10.2. Instruments
  - 5.10.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.10.3. Reagents
  - 5.10.3.1. Reagents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.10.4. Others
  - 5.10.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Infectious Disease Molecular Diagnostics Market: Application Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Infectious Disease Molecular Diagnostics Market: Application Movement Analysis, 2024 & 2030 (USD Million)
6.3. Respiratory Diseases
- 6.3.1. Respiratory Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Tuberculosis
- 6.4.1. Tuberculosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Meningitis
- 6.5.1. Meningitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Gastrointestinal Tract Infections
- 6.6.1. Gastrointestinal Tract Infections Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. HPV
- 6.7.1. HPV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Sexually Transmitted Infections
- 6.8.1. Sexually Transmitted Infections Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Sepsis
- 6.9.1. Sepsis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.10. Drug Resistance Diseases
- 6.10.1. Drug Resistance Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.11. Others
- 6.11.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Infectious Disease Molecular Diagnostics Market: End Use Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Infectious Disease Molecular Diagnostics Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
7.3. Hospitals
- 7.3.1. Hospitals Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Clinics
- 7.4.1. Clinics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Diagnostics Laboratories
- 7.5.1. Diagnostics Laboratories Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Research Institutes
- 7.6.1. Research Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Infectious Disease Molecular Diagnostics Market: Regional Estimates & Trend Analysis

8.1. Infectious Disease Molecular Diagnostics Market Share, By Region, 2024 & 2030 (USD Million)
8.2. North America
- 8.2.1. North America Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.2. U.S.
  - 8.2.2.1. U.S. Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.3. Canada
  - 8.2.3.1. Canada Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.4. Mexico
  - 8.2.4.1. Mexico Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
- 8.3.1. Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2. UK
  - 8.3.2.1. UK Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Germany
  - 8.3.3.1. Germany Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4. France
  - 8.3.4.1. France Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.5. Italy
  - 8.3.5.1. Italy Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.6. Spain
  - 8.3.6.1. Spain Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.7. Denmark
  - 8.3.7.1. Denmark Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.8. Sweden
  - 8.3.8.1. Sweden Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.9. Norway
  - 8.3.9.1. Norway Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
- 8.4.1. Asia Pacific Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. Japan
  - 8.4.2.1. Japan Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. China
  - 8.4.3.1. China Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. India
  - 8.4.4.1. India Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.5. Australia
  - 8.4.5.1. Australia Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.6. South Korea
  - 8.4.6.1. South Korea Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.7. Thailand
  - 8.4.7.1. Thailand Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
- 8.5.1. Latin America Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Brazil
  - 8.5.2.1. Brazil Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Argentina
  - 8.5.3.1. Argentina Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Middle East and Africa
- 8.6.1. Middle East and Africa Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. South Africa
  - 8.6.2.1. South Africa Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. Saudi Arabia
  - 8.6.3.1. South Africa Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. UAE
  - 8.6.4.1. UAE Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Kuwait
  - 8.6.5.1. Kuwait Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
- 9.4.1. Abbott
  - 9.4.1.1. Participant's Overview
  - 9.4.1.2. Financial Performance
  - 9.4.1.3. Product Benchmarking
  - 9.4.1.4. Recent Developments/ Strategic Initiatives
- 9.4.2. Danaher Corporation
  - 9.4.2.1. Participant's Overview
  - 9.4.2.2. Financial Performance
  - 9.4.2.3. Product Benchmarking
  - 9.4.2.4. Recent Developments/ Strategic Initiatives
- 9.4.3. bioMerieux SA
  - 9.4.3.1. Participant's Overview
  - 9.4.3.2. Financial Performance
  - 9.4.3.3. Product Benchmarking
  - 9.4.3.4. Recent Developments/ Strategic Initiatives
- 9.4.4. F. Hoffmann-La Roche Ltd
  - 9.4.4.1. Participant's Overview
  - 9.4.4.2. Financial Performance
  - 9.4.4.3. Product Benchmarking
  - 9.4.4.4. Recent Developments/ Strategic Initiatives
- 9.4.5. Bio-Rad Laboratories, Inc.
  - 9.4.5.1. Participant's Overview
  - 9.4.5.2. Financial Performance
  - 9.4.5.3. Product Benchmarking
  - 9.4.5.4. Recent Developments/ Strategic Initiatives
- 9.4.6. Agilent Technologies, Inc.
  - 9.4.6.1. Participant's Overview
  - 9.4.6.2. Financial Performance
  - 9.4.6.3. Product Benchmarking
  - 9.4.6.4. Recent Developments/ Strategic Initiatives
- 9.4.7. Becton, Dickinson and Company
  - 9.4.7.1. Participant's Overview
  - 9.4.7.2. Financial Performance
  - 9.4.7.3. Product Benchmarking
  - 9.4.7.4. Recent Developments/ Strategic Initiatives
- 9.4.8. Hologic, Inc. (Gen-Probe)
  - 9.4.8.1. Participant's Overview
  - 9.4.8.2. Financial Performance
  - 9.4.8.3. Product Benchmarking
  - 9.4.8.4. Recent Developments/ Strategic Initiatives
- 9.4.9. Grifols S.A.
  - 9.4.9.1. Participant's Overview
  - 9.4.9.2. Financial Performance
  - 9.4.9.3. Product Benchmarking
  - 9.4.9.4. Recent Developments/ Strategic Initiatives
- 9.4.10. Qiagen
  - 9.4.10.1. Participant's Overview
  - 9.4.10.2. Financial Performance
  - 9.4.10.3. Product Benchmarking
  - 9.4.10.4. Recent Developments/ Strategic Initiatives
- 9.4.11. Siemens Healthineers AG
  - 9.4.11.1. Participant's Overview
  - 9.4.11.2. Financial Performance
  - 9.4.11.3. Product Benchmarking
  - 9.4.11.4. Recent Developments/ Strategic Initiatives
- 9.4.12. Sysmex Corporation
  - 9.4.12.1. Participant's Overview
  - 9.4.12.2. Financial Performance
  - 9.4.12.3. Product Benchmarking
  - 9.4.12.4. Recent Developments/ Strategic Initiatives